Compare Natera Inc. Common Stock (NTRA) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Natera Inc. Common Stock trades at $394.16 (market cap $57.03B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.53 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vanguard Intermediate Term Corporate Bond ETF for 64 Days on average.
| NTRA | VCIT | |
|---|---|---|
Market Cap | $57.03B | $72.20B |
Volume | 1,131,157 | 9,562,318 |
Sector | Health | Fixed Income |
52-Week High | $425.64 | $84.82 |
52-Week Low | $179.42 | $77.98 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VCIT trades at $78.48, down slightly by 0.03% with a bullish technical signal supported by oscillators despite bearish moving averages. The ETF maintains consistent dividend payments of $0.34 per share and shows strong institutional interest with recent purchases by Engineers Gate Manager LP and HB Wealth Management. Technical analysis indicates key support at $78 and resistance at $80.
VCIT offers a compelling risk-return profile with a 4.8% yield and 5.1% yield to maturity, benefiting from low 0.03% expense ratio. Risks include interest rate sensitivity and corporate credit exposure, but the fund's intermediate-term corporate bond focus provides balanced income generation for investors seeking steady returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
